JPWO2019141780A5 - - Google Patents

Claims (12)

A kit containing reagents suitable for measuring the ratio of succinate-producing bacteria to succinate-consuming bacteria in a subject-derived fecal sample.
The kit comprises a primer set designed to specifically hybridize to the hypervariable region of the 16S rRNA gene in at least one succinate-producing bacterium and at least one succinate-consuming bacterium, or the kit includes at least one. Includes probes that specifically hybridize to the hypervariable region of the 16S rRNA gene in succinate-producing and at least one succinate-consuming bacterium.
The primer set or the probe constitutes at least 10% of the total amount of reagents forming the kit.
kit. Use of the kit according to claim 1 for detecting the ratio of succinate-producing bacteria to succinate-consuming bacteria in a stool sample derived from a subject. The use of a kit for determining whether the succinate level in a subject-derived body fluid sample is higher than the threshold level, wherein the kit measures the succinate level in the subject-derived body fluid sample. Contains suitable reagents for
The presence of succinate above a predetermined threshold level in the fluid sample provides a positive result.
The presence of succinate below a predetermined threshold level in the biofluid sample or the absence of succinate in the biofluid sample provides a negative result.
use. The use of a kit to determine if a probiotic intervention aimed at reducing the level of circulating succinate in a subject was effective, said kit being the succinate level in a body fluid sample from the subject. Contains reagents suitable for measurement of
The level of circulating succinate in the body fluid sample from the subject after the probiotic intervention, which is lower than the level of circulating succinate in the body fluid sample from the subject before the probiotic intervention. Showing that the probiotic intervention was effective,
Circulating succinate in the body fluid sample from the subject after the probiotic intervention that is equal to or higher than the level of the circulating succinate in the body fluid sample from the subject before the probiotic intervention. Level indicates that the probiotic intervention was not effective, use. A method for determining whether a targeted intervention aimed at reducing the level of circulating succinate in a subject was effective.
(A) The step of measuring the ratio of the succinate-producing bacteria to the succinate-consuming bacteria in the stool sample derived from the subject before the targeting intervention, and (b) the stool sample derived from the subject after the targeting intervention. Including the step of measuring the ratio of succinate-producing bacteria to succinate-consuming bacteria in
With succinate-producing bacteria in the stool sample from the subject after the targeting intervention, which is lower than the ratio of succinate-producing bacteria in the stool sample from the subject before the targeting intervention to succinate-consuming bacteria. The ratio to succinate-consuming bacteria indicates that the targeted intervention was effective.
• In the stool sample from the subject after the targeting intervention that is equal to or higher than the ratio of succinate-producing bacteria to succinate-consuming bacteria in the stool sample from the subject before the targeting intervention. The ratio of succinate-producing bacteria to succinate-consuming bacteria indicates that the targeted intervention was ineffective.
Method. A dietary intervention or diet composition for preventing and / or treating a disease associated with high levels of circulating succinate in a patient, wherein the intervention or composition is a succinate-producing bacterium and succinate consumption in the patient's intestinal tract. A dietary intervention or diet composition that reduces the ratio to bacteria. A pharmaceutical or probiotic composition for preventing and / or treating a disease associated with high levels of circulating succinate, wherein the composition is a succinate-producing bacterium and a succinate-consuming bacterium in the patient's intestinal tract. A pharmaceutical or probiotic composition that reduces the ratio of, or said composition, reduces the level of circulating succinate in a patient . The group of the above-mentioned diseases associated with high levels of circulatory succinate in patients consists of obesity, cardiovascular disease, hypertension, type 2 diabetes, chronic heart failure, ischemic heart disease, ischemic / reperfusion injury and diabetic nephropathy. The dietary intervention or diet composition according to claim 6 , or the pharmaceutical composition or probiotics composition according to claim 7 . The dietary intervention or diet composition according to claim 6 or 8 , or the pharmaceutical composition according to claim 7 , wherein the ratio of the succinate-producing bacterium to the succinate-consuming bacterium is the ratio of (Prebioticasee + Vellonellaceae) / (Odribacteriaceae + Clostridiaceae). Object or probiotic composition . Odoribacter spp. , Clostridium spp. , Phascolarctobacterium spp. , Ruminococcus spp. The probiotic composition according to any one of claims 7 to 9 , which comprises a succinate-consuming bacterium selected from the group consisting of and a combination thereof. A probiotic composition comprising an effective amount of succinate-consuming bacteria, wherein the succinate-consuming bacteria are described in Odoribacter spp. , Phascolarctobacterium spp. , Ruminococcus spp. And a probiotic composition selected from the group consisting of combinations thereof . 11. The probiotic composition of claim 11 , wherein the succinate-consuming bacterium is selected from the group consisting of Phascolarctobacterium succinatutens, Phascolarctobacteriaium faecium, Ruminococcus bromii and Odoribacter laneus.